Gastrin ameliorates heart failure and suppresses myocardial remodeling via the JAK2/STAT3 and ERK1/2 pathways
Fig 5
The myocardial protective effect of gastrin through JAK2/STAT3 and ERK1/2 pathways in vivo.
In the control, gastrin, ISO, and ISO+gastrin groups:(A)The protein expression levels of JAK2,p-JAK2, STAT3, p-STAT3, ERK1/2, (p-ERK, and GAPDH by Western blot; (B)The level of p-JAK2/JAK2; (C)The level of p-STAT3/STAT3; (D)The level of p-ERK/ERK; In the control, ISO, ISO+gastrin, and ISO+gastrin+CI-988 groups: (E)The protein expression levels of JAK2,p-JAK2, STAT3, p-STAT3, ERK1/2, p-ERK, and GAPDH by Western blot; (F)The level of p-JAK2/JAK2; (G)The level of p-STAT3/STAT3; (H)The level of p-ERK/ERK.*P < 0.05, **P < 0.01,***P < 0.001, ****P < 0.0001. The data are presented as the mean±SEM. One-way ANOVA with Tukey’s post-hoc was conducted for (Panel B-D,F-H).